healthcare products regulatory agency: Live & Latest News Updates : Vimarsana.com

AriBio Co., Ltd.: AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer's Disease (POLARIS-AD)

AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer's Disease (POLARIS-AD) | Region

SEONGNAM-SI, South Korea--(BUSINESS WIRE)--Apr 28, 2024--

AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer's Disease (POLARIS-AD)

Interview: Wendy Cheng on global AI regulation in pharmaceuticals

OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal...

AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer's Disease (POLARIS-AD)

Mundipharma acquires all assets and rights related to REZZAYO (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area

Regulated vapes are paramount as illegal vape seizures rise across the UK

Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024